Datasets:

bvand086
/

ata_guidelines

Dataset card Viewer Files Files and versions Community

Split (1)

train · 847 rows

text stringlengths 6 1.29k
nostic signiﬁcance of lymph node metastasis and multi- focality. Cancer 98:31–40. 146. Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS, Thompson GB, Sebo TJ, Goellner JR 2008 Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 144:980–987. 147. Roti E, degli Uberti EC, B ondanelli M, Braverman LE 2008 Thyroid papillary microcarcinoma: a descrip- tive and meta-analysis study. Eur J Endocrinol 159: 659–673. 148. Giordano D, Gradoni P, Oretti G, Molina E, Ferri T 2010 Treatment and prognostic factors of papillary thyroidmicrocarcinoma. Clin Otolaryngol 35:118–124. 149. Ito Y, Miyauchi A, Inoue H, Fukushima M, Kihara M, Higashiyama T, Tomoda C, Takamura Y, Kobayashi K, Miya A 2010 An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg 34: 28–35. 150. Niemeier LA, Kuffner AH, Song C, Carty SE, Hodak SP, Yip L, Ferris RL, Tseng GC, Seethala RR,
LeBeau SO, Stang MT, Coyne C, Johnson JT, Stewart AF, Nikiforov YE 2012 A combined molecular-pathologic score im- proves risk stratiﬁcation of thyroid papillary micro- carcinoma. Cancer 118:2069–2077. 151. Roh JL, Kim JM, Park CI 2008 Central cervical nodal metastasis from papillary thyroid microcarcinoma: pat- tern and factors predictive of nodal metastasis. Ann Surg Oncol 15:2482–2486. 152. Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ, Qu JM 2010 The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol 17:3294–3300. 153. Zheng X, Wei S, Han Y, Li Y, Yu Y, Yun X, Ren X, Gao M 2013 Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol 20:2266–2273. 154. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, Castro P, Prazeres H, Lima
J, Amaro T, Lobo C, Martins MJ, Moura M, Cavaco B, Leite V, Cameselle-Teijeiro JM, Carrilho F, Carvalheiro M, Maximo V, Sobrinho-Simoes M, Soares P 2014 TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carci- nomas. J Clin Endocrinol Metab 99:E754-E765. 155. Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S, Bishop J 2014 BRAFV600Eand TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 32:2718–2726. 156. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differen- tiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399–5404. 157. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, He- guy A, Ladanyi
M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA 2009 Mutational proﬁle of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct patho- genetic roles for BRAF, PIK3CA, and AKT1. Cancer Res69:4885–4893.158. Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Mar- cucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML 2011 NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 9(Suppl 5): S1–S32. 159. Bernet V, Hupart KH, Parangi S, Woeber KA 2014 AACE/ACE disease state commentary: molecular diag- nostic testing of thyroid nodules with indeterminate cy- topathology. Endocr Pract 20:360–363. 160. Ferris RL, Baloch Z, Bernet V, Chen A, Fahey TJ III, Ganly I, Hodak SP, Kebebew E, Patel KN, Shaha A, Steward DL, Tufano RP, Wiseman SM, Carty SE;American Thyroid Association Surgical Affairs Com-
mittee 2015 American Thyroid Association Statement on Surgical Application of Molecular Proﬁling for Thyroid Nodules: Current Impact on Perioperative Decision Making. Thyroid 25:760–768. 161. Xing M, Haugen BR, Schlumberger M 2013 Progress in molecular-based management of differentiated thyroid cancer. Lancet 381:1058–1069. 162. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau S O ,F e r r i sR L ,Y i pL ,S e e t h a l aR R ,T u b l i nM E ,S t a n g MT, Coyne C, Johnson JT, Stewart AF, Nikiforova MN 2011 Impact of mutational testing on the diag- nosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 96: 3390–3397. 163. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward
DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB, Haugen BR 2012 Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 367:705–715. 164. Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, Palestini N, Ghigo E, Papotti M, Bussolati G, Martegani MP, Pantellini F, Carpi A, Gio- vagnoli MR, Monti S, Toscano V, Sciacchitano S, Pen- nelli GM, Mian C, Pelizzo MR, Rugge M, Troncone G, Palombini L, Chiappetta G, Botti G, Vecchione A, Bel- locco R 2008 Galectin-3-expression analysis in the sur- gical selection of follicular thyroid nodules with indeterminate ﬁne-needle aspiration cytology: a pro- spective multicentre study. Lancet Oncol 9:543–549. 165. Nikiforov YE, Steward DL, Robinson-Smith TM, Hau- gen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN 2009 Molecular testing for mutations in improving the ﬁne-needle aspiration diag- nosis of thyroid nodules. J Clin Endocrinol Metab
94: 2092–2098. 166. Moses W, Weng J, Sansano I, Peng M, Khanafshar E, Ljung BM, Duh QY, Clark OH, Kebebew E 2010 Mo- lecular testing for somatic mutations improves the ac- curacy of thyroid ﬁne-needle aspiration biopsy. World J Surg 34:2589–2594. 167. Beaudenon-Huibregtse S, Alexander EK, Guttler RB, Hershman JM, Babu V, Blevins TC, Moore P, Andruss B, Labourier E 2014 Centralized molecular testing for oncogenic gene mutations complements the local cyto- pathologic diagnosis of thyroid nodules. Thyroid 24: 1479–1487. 168. Liu S, Gao A, Zhang B, Zhang Z, Zhao Y, Chen P, Ji M, Hou P, Shi B 2014 Assessment of molecular testing in98 HAUGEN ET AL.
ﬁne-needle aspiration biopsy samples: an experience in a Chinese population. Exp Mol Pathol 97:292–297. 169. Nikiforov YE, Nikiforova MN 2011 Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 7: 569–580. 170. Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, Gooding WE, Hodak SP, LeBeau SO, Ohori NP, Seethala RR, Tublin ME, Yip L, Nikiforova MN 2014 Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follic- ular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer 120:3627–3634. 171. Alexander EK, Schorr M, Klopper J, Kim C, Sipos J, Nabhan F, Parker C, Steward DL, Mandel SJ, Haugen BR 2014 Multicenter clinical experience with the Aﬁrma gene expression classiﬁer. J Clin Endocrinol Metab 99: 119–125. 172. Harrell RM, Bimston DN 2014 Surgical utility of Aﬁr- ma: effects of high cancer prevalence and oncocytic cell types in patients with indeterminate thyroid cytology.
Endocr Pract 20:364–369. 173. McIver B, Castro MR, Morris JC, Bernet V, Smallridge R, Henry M, Kosok L, Reddi H 2014 An independent study of a gene expression classiﬁer (Aﬁrma) in the evaluation of cytologically indeterminate thyroid nod- ules. J Clin Endocrinol Metab 99:4069–4077. 174. Marti JL, Avadhani V, Donatelli LA, Niyogi S, Wang B, Wong RJ, Shaha AR, Ghossein RA, Lin O, Morris LG, Ho AS 2015 Wide inter-institutional variation in per- formance of a molecular classiﬁer for indeterminate thyroid nodules. Ann Surg Oncol 22:3996–4001. 175. Franco C, Martinez V, Allamand JP, Medina F, Glasi- novic A, Osorio M, Schachter D 2009 Molecular markers in thyroid ﬁne-needle aspiration biopsy: a prospective study. Appl Immunohistochem Mol Morphol 17:211– 215. 176. Fadda G, Rossi ED, Raffaelli M, Pontecorvi A, Sioletic S, Morassi F, Lombardi CP, Zannoni GF, Rindi G 2011 Follicular thyroid neoplasms can be classiﬁed as low- and high-risk according
to HBME-1 and Galectin-3 ex- pression on liquid-based ﬁne-needle cytology. Eur J Endocrinol 165:447–453. 177. Lubitz CC, Fahey TJ III 2005 The differentiation of benign and malignant thyroid nodules. Adv Surg 39: 355–377. 178. Prasad NB, Somervell H, Tufano RP, Dackiw AP, Marohn MR, Califano JA, Wang Y, Westra WH, Clark DP, Umbricht CB, Libutti SK, Zeiger MA 2008 Identi- ﬁcation of genes differentially expressed in benign ver- sus malignant thyroid tumors. Clin Cancer Res 14:3327– 3337. 179. Lappinga PJ, Kip NS, Jin L, Lloyd RV, Henry MR, Zhang J, Nassar A 2010 HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules. Cancer Cyto- pathol 118:287–297. 180. Chen YT, Kitabayashi N, Zhou XK, Fahey TJ III, Scognamiglio T 2008 MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol 21:1139–1146. 181. Nikiforova MN, Tseng GC, Steward D, Diorio D, Niki- forov
YE 2008 MicroRNA expression proﬁling of thy- roid tumors: biological signiﬁcance and diagnostic utility. J Clin Endocrinol Metab 93:1600–1608.182. Mazeh H, Mizrahi I, Halle D, Ilyayev N, Stojadinovic A, Trink B, Mitrani-Rosenbaum S, Roistacher M, Ariel I, Eid A, Freund HR, Nissan A 2011 Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid 21:111–118. 183. Shen R, Liyanarachchi S, Li W, Wakely PE Jr, Saji M, Huang J, Nagy R, Farrell T, Ringel MD, de la Chapelle A, Kloos RT, He H 2012 MicroRNA signature in thyroid ﬁne needle aspiration cytology applied to ‘‘atypia of undetermined signiﬁcance’’ cases. Thyroid22:9–16. 184. Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scog- namiglio T, Hoda R, Buitrago D, Cooper D, Zeiger MA, Zarnegar R, Elemento O, Fahey TJ III 2012 A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on
ﬁne needle as- piration. Clin Cancer Res 18:2032–2038. 185. Agretti P, Ferrarini E, Rago T, Candelieri A, De Marco G, Dimida A, Niccolai F, Molinaro A, Di Coscio G, Pinchera A, Vitti P, Tonacchera M 2012 MicroRNA expression proﬁle helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of ﬁne- needle aspiration. Eur J Endocrinol 167: 393–400. 186. Labourier E, Shifrin A, Busseniers AE, Lupo MA, Man- ganelli ML, Andruss B, Wylie D, Beaudenon-Huibregtse S 2015 Molecular testing for miRNA, mRNA, and DNA on ﬁne-needle aspiration improves the preoperative diag- nosis of thyroid nodules with indeterminate cytology. J Clin Endocrinol Metab 100:2743–2750. 187. Milas M, Shin J, Gupta M, Novosel T, Nasr C, Brainard J, Mitchell J, Berber E, Siperstein A 2010 Circulating thyrotropin receptor mRNA as a novel marker of thyroid cancer: clinical applications learned from 1758 samples. Ann Surg 252:643–651. 188. McGovern MM, Benach MO,
Wallenstein S, Desnick RJ, Keenlyside R 1999 Quality assurance in molecular genetic testing laboratories. JAMA 281:835–840. 189. McGovern MM, Elles R, Beretta I, Somerville MJ, Hoeﬂer G, Keinanen M, Barton D, Carson N, Dequeker E, Brdicka R, Blazkova A, Ayme S, Schnieders B, Muller CR, Dalen V, Martinez AA, Kristoffersson U, Ozguc M, Mueller H, Boone J, Lubin IM, Sequeiros J, Taruscio D, Williamson B, Mainland L, Yoshikura H, Ronchi E 2007 Report of an international survey ofmolecular genetic testing laboratories. Community Genet 10:123–131. 190. Krane JF, Nayar R, Renshaw AA 2010 Atypia of unde- termined signiﬁcance/follicular lesion of undetermined signiﬁcance. In: Ali SZ, Cibas ES (eds) The Bethesda System for Reporting Thyroid Cytopathology. Springer, pp 37–49. 191. Bongiovanni M, Crippa S, Baloch Z, Piana S, Spitale A, Pagni F, Mazzucchelli L, Di BC, Faquin W 2012 Com- parison of 5-tiered and 6-tiered diagnostic systems for the reporting of thyroid
cytopathology: a multi- institutional study. Cancer Cytopathol 120:117–125. 192. Davidov T, Trooskin SZ, Shanker BA, Yip D, Eng O, Crystal J, Hu J, Chernyavsky VS, Deen MF, May M, Artymyshyn RL 2010 Routine second-opinion cyto- pathology review of thyroid ﬁne needle aspiration bi- opsies reduces diagnostic thyroidectomy. Surgery 148: 1294–1299.ATA THYROID NODULE/DTC GUIDELINES 99
193. Baloch Z, LiVolsi VA, Jain P, Jain R, Aljada I, Mandel S, Langer JE, Gupta PK 2003 Role of repeat ﬁne-needle aspiration biopsy (FNAB) in the management of thyroid nodules. Diagn Cytopathol 29:203–206. 194. Yassa L, Cibas ES, Benson CB, Frates MC, Doubilet PM, Gawande AA, Moore FD Jr, Kim BW, Nose V, Marqusee E, Larsen PR, Alexander EK 2007 Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer 111:508–516. 195. Yang J, Schnadig V, Logrono R, Wasserman PG 2007 Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer 111:306–315. 196. Vanderlaan PA, Marqusee E, Krane JF 2011 Clinical outcome for atypia of undetermined signiﬁcance in thyroid ﬁne-needle aspirations: should repeated fna be the pre- ferred initial approach? Am J Clin Pathol 135:770–775. 197. Nasrollah N, Trimboli P, Rossi F, Amendola S, Guidobaldi L, Ventura C, Maglio R, Nigri
G, Romanelli F, Valabrega S, Crescenzi A 2014 Patient’s comfort with and tolera- bility of thyroid core needle biopsy. Endocrine 45:79–83. 198. Kim SK, Hwang TS, Yoo YB, Han HS, Kim DL, Song KH, Lim SD, Kim WS, Paik NS 2011 Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin En- docrinol Metab 96:658–664. 199. Adeniran AJ, Hui P, Chhieng DC, Prasad ML, Schoﬁeld K, Theoharis C 2011 BRAF mutation testing of thyroid ﬁne-needle aspiration specimens enhances the predict- ability of malignancy in thyroid follicular lesions of undetermined signiﬁcance. Acta Cytol 55:570–575. 200. Lastra RR, Pramick MR, Crammer CJ, LiVolsi VA, Baloch ZW 2014 Implications of a suspicious aﬁrma test result in thyroid ﬁne-needle aspiration cytology: an in- stitutional experience. Cancer Cytopathol 122:737–744. 201. Jeong SH, Hong HS, Lee EH, Cha JG, Park JS, Kwak JJ 2013 Outcome of thyroid nodules
characterized as atypia of undetermined signiﬁcance or follicular lesion of un- determined signiﬁcance and correlation with ultrasound features and BRAF(V600E) mutation analysis. AJR Am J Roentgenol 201:W854–W860. 202. Yoo WS, Choi HS, Cho SW, Moon JH, Kim KW, Park HJ, Park SY, Choi SI, Choi SH, Lim S, Yi KH, Park do J, Jang HC, Park YJ 2014 The role of ultrasound ﬁndings in the management of thyroid nodules with atypia or fol- licular lesions of undetermined signiﬁcance. Clin En-docrinol (Oxf) 80:735–742. 203. Gweon HM, Son EJ, Youk JH, Kim JA 2013 Thyroid nodules with Bethesda system III cytology: can ultraso- nography guide the next step? Ann Surg Oncol 20:3083– 3088. 204. Kim DW, Lee EJ, Jung SJ, Ryu JH, Kim YM 2011 Role of sonographic diagnosis in managing Bethesda class III nodules. AJNR Am J Neuroradiol 32:2136–2141. 205. Rosario PW 2014 Thyroid nodules with atypia or fol- licular lesions
of undetermined signiﬁcance (Bethesda Category III): importance of ultrasonography and cyto- logical subcategory. Thyroid 24:1115–1120. 206. Henry MR, DeMay RM, Berezowski K 2010 Follicular neoplasm/suspicious for a follicular neoplasm. In: Ali SZ, Cibas ES (eds) The Bethesda System for Reporting Thyroid Cytopathology. Springer, pp 51–58. 207. Faquin WC, Michael CW, Renshaw AA 2010 Follicular neoplasm, Hu ¨rthle cell type/suspicious for a follicularneoplasm, Hu ¨rthle cell type. In: Ali SZ, Cibas ES (eds) The Bethesda System for Reporting Thyroid Cyto- pathology. Springer, pp 59–73. 208. Gupta N, Dasyam AK, Carty SE, Nikiforova MN, Ohori NP, Armstrong M, Yip L, LeBeau SO, McCoy KL, Coyne C, Stang MT, Johnson J, Ferris RL, Seethala R, Nikiforov YE, Hodak SP 2013 RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. J Clin EndocrinolMetab 98:E914–E922. 209. Wang HH, Filie AC, Clark DP 2010 Suspicious for malignancy. In: Ali SZ, Cibas
ES (eds) The Bethesda System for Reporting Thyroid Cytopathology. Springer,pp 75–89. 210. Moon HJ, Kwak JY, Kim EK, Choi JR, Hong SW, Kim MJ, Son EJ 2009 The role of BRAFV600E mutation and ultrasonography for the surgical management of a thy- roid nodule suspicious for papillary thyroid carcinoma on cytology. Ann Surg Oncol 16:3125–3131. 211. Adeniran AJ, Theoharis C, Hui P, Prasad ML, Hammers L, Carling T, Udelsman R, Chhieng DC 2011 Reﬂex BRAF testing in thyroid ﬁne-needle aspiration biopsy with equivocal and positive interpretation: a prospective study. Thyroid 21:717–723. 212. Jara SM, Bhatnagar R, Guan H, Gocke CD, Ali SZ, Tufano RP 2014 Utility of BRAF mutation detection in ﬁne-needle aspiration biopsy samples read as ‘‘suspi- cious for papillary thyroid carcinoma’’. Head Neck doi: 10.1002/hed.23829. [Epub ahead of print]. 213. de Geus-Oei LF, Pieters GF, Bonenkamp JJ, Mudde AH, Bleeker-Rovers CP, Corstens FH, Oyen WJ 2006 18F- FDG PET
reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. J Nucl Med 47:770–775. 214. Kresnik E, Gallowitsch HJ, Mikosch P, Stettner H, Igerc I, Gomez I, Kumnig G, Lind P 2003 Fluorine-18- ﬂuorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an en- demic goiter area. Surgery 133:294–299. 215. Kim JM, Ryu JS, Kim TY, Kim WB, Kwon GY, Gong G, Moon DH, Kim SC, Hong SJ, Shong YK 2007 18F- ﬂuorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. J Clin Endocrinol Metab 92:1630–1634. 216. Sebastianes FM, Cerci JJ, Zanoni PH, Soares J Jr, Chi- bana LK, Tomimori EK, de Camargo RY, Izaki M, Giorgi MC, Eluf-Neto J, Meneghetti JC, Pereira MA 2007 Role of 18F-ﬂuorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 92:4485–4488. 217. Hales NW, Krempl GA, Medina
JE 2008 Is there a role for ﬂuorodeoxyglucose positron emission tomography/ computed tomography in cytologically indeterminate thyroid nodules? Am J Otolaryngol 29:113–118. 218. Traugott AL, Dehdashti F, Trinkaus K, Cohen M, Fialk- owski E, Quayle F, Hussain H, Davila R, Ylagan L, Moley JF 2010 Exclusion of malignancy in thyroid nodules with indeterminate ﬁne-needle aspiration cytology after nega- tive 18F-ﬂuorodeoxyglucose positron emission tomogra- phy: interim analysis. World J Surg 34:1247–1253. 219. Smith RB, Robinson RA, Hoffman HT, Graham MM 2008 Preoperative FDG-PET imaging to assess the ma-100 HAUGEN ET AL.
lignant potential of follicular neoplasms of the thyroid. Otolaryngol Head Neck Surg 138:101–106. 220. Deandreis D, Al Ghuzlan A, Auperin A, Vielh P, Caillou B, Chami L, Lumbroso J, Travagli JP, Hartl D, Baudin E, Schlumberger M, Leboulleux S 2012 Is (18)F- ﬂuorodeoxyglucose-PET/CT useful for the presurgical characterization of thyroid nodules with indeterminate ﬁne needle aspiration cytology? Thyroid 22:165–172. 221. Vriens D, de Wilt JH, van der Wilt GJ, Netea-Maier RT, Oyen WJ, de Geus-Oei LF 2011 The role of [18F]-2- ﬂuoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate ﬁne-needle aspi- ration biopsy: systematic review and meta-analysis of theliterature. Cancer 117:4582–4594. 222. Wang N, Zhai H, Lu Y 2013 Is ﬂuorine-18 ﬂuorodeox- yglucose positron emission tomography useful for the thyroid nodules with indeterminate ﬁne needle aspiration biopsy? A meta-analysis of the literature. J Otolaryngol Head Neck Surg 42:38–45. 223. Vriens D, Adang EM, Netea-Maier RT, Smit JW, de Wilt JH,
Oyen WJ, de Geus-Oei LF 2014 Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach. J Clin Endocrinol Metab 99:3263–3274. 224. Duren M, Yavuz N, Bukey Y, Ozyegin MA, Gundogdu S, Acbay O, Hatemi H, Uslu I, Onsel C, Aksoy F, Oz F, Unal G, Duren E 2000 Impact of initial surgical treat- ment on survival of patients with differentiated thyroid cancer: experience of an endocrine surgery center in an iodine-deﬁcient region. World J Surg 24:1290–1294. 225. Stojadinovic A, Peoples GE, Libutti SK, Henry LR, Eberhardt J, Howard RS, Gur D, Elster EA, Nissan A 2009 Development of a clinical decision model for thy- roid nodules. BMC Surg 9:12. 226. Tuttle RM, Lemar H, Burch HB 1998 Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasia by ﬁne-needle aspi- ration. Thyroid 8:377–383. 227. Goldstein RE, Netterville JL, Burkey B, Johnson JE
2002 Implications of follicular neoplasms, atypia, and lesions suspicious for malignancy diagnosed by ﬁne-needle aspi- ration of thyroid nodules. Ann Surg 235:656–662. 228. Schlinkert RT, van Heerden JA, Goellner JR, Gharib H, Smith SL, Rosales RF, Weaver AL 1997 Factors that predict malignant thyroid lesions when ﬁne-needle as- piration is ‘‘suspicious for follicular neoplasm’’. MayoClin Proc 72:913–916. 229. Mehta RS, Carty SE, Ohori NP, Hodak SP, Coyne C, LeBeau SO, Tublin ME, Stang MT, Johnson JT, McCoy KL, Nikiforova MN, Nikiforov YE, Yip L 2013 Nodule size is an independent predictor of malignancy in mutation-negative nodules with follicular lesion of un- determined signiﬁcance cytology. Surgery 154:730–736. 230. McCoy KL, Carty SE, Armstrong MJ, Seethala RR, Ohori NP, Kabaker AS, Stang MT, Hodak SP, Nikiforov YE, Yip L 2012 Intraoperative pathologic examination in the era of molecular testing for differentiated thyroid cancer. J Am Coll Surg 215:546–554. 231. Kandil E, Krishnan
B, Noureldine SI, Yao L, Tufano RP 2013 Hemithyroidectomy: a meta-analysis of postoper- ative need for hormone replacement and complications. ORL J Otorhinolaryngol Relat Spec 75:6–17. 232. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R 1998 The importance of surgeon ex-perience for clinical and economic outcomes from thy- roidectomy. Ann Surg 228:320–330. 233. Loyo M, Tufano RP, Gourin CG 2013 National trends in thyroid surgery and the effect of volume on short-term outcomes. Laryngoscope 123:2056–2063. 234. Verloop H, Louwerens M, Schoones JW, Kievit J, Smit JW, Dekkers OM 2012 Risk of hypothyroidism follow- ing hemithyroidectomy: systematic review and meta- analysis of prognostic studies. J Clin Endocrinol Metab 97:2243–2255. 235. Brito JP, Yarur AJ, Prokop LJ, McIver B, Murad MH, Montori VM 2013 Prevalence of thyroid cancer in multinodular goiter versus single nodule: a systematicreview and meta-analysis. Thyroid 23:449–455. 236. Kwak JY, Koo H, Youk JH, Kim
MJ, Moon HJ, Son EJ, Kim EK 2010 Value of US correlation of a thyroid nodule with initially benign cytologic results. Radiology 254:292–300. 237. Brauer VF, Eder P, Miehle K, Wiesner TD, Hasenclever H, Paschke R 2005 Interobserver variation for ultrasound determination of thyroid nodule volumes. Thyroid 15: 1169–1175. 238. Alexander EK, Hurwitz S, Heering JP, Benson CB, Frates MC, Doubilet PM, Cibas ES, Larsen PR, Mar- qusee E 2003 Natural history of benign solid and cystic thyroid nodules. Ann Intern Med 138:315–318. 239. Papini E, Petrucci L, Guglielmi R, Panunzi C, Rinaldi R, Bacci V, Crescenzi A, Nardi F, Fabbrini R, Pacella CM 1998 Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppres- sive therapy for benign cold thyroid nodules. J Clin Endocrinol Metab 83:780–783. 240. Erdogan MF, Gursoy A, Erdogan G 2006 Natural course of benign thyroid nodules in a moderately iodine- deﬁcient area.
Clin Endocrinol (Oxf) 65:767–771. 241. Durante C, Costante G, Lucisano G, Bruno R, Meringolo D, Paciaroni A, Puxeddu E, Torlontano M, Tumino S, Attard M, Lamartina L, Nicolucci A, Filetti S 2015 The natural history of benign thyroid nodules. JAMA 313: 926–935. 242. Rosario PW, Purisch S 2010 Ultrasonographic charac- teristics as a criterion for repeat cytology in benign thyroid nodules. Arq Bras Endocrinol Metabol 54: 52–55. 243. Zelmanovitz F, Genro S, Gross JL 1998 Suppressive therapy with levothyroxine for solitary thyroid nodules: adouble-blind controlled clinical study and cumulative meta-analyses. J Clin Endocrinol Metab 83:3881–3885. 244. Wemeau JL, Caron P, Schvartz C, Schlienger JL, Or- giazzi J, Cousty C, Vlaeminck-Guillem V 2002 Effects of thyroid-stimulating hormone suppression with le- vothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable chan- ges: a randomized, double-blind, placebo-controlled trial by the French Thyroid Research Group. J Clin En- docrinol Metab
87:4928–4934. 245. Castro MR, Caraballo PJ, Morris JC 2002 Effectiveness of thyroid hormone suppressive therapy in benign soli- tary thyroid nodules: a meta-analysis. J Clin Endocrinol Metab 87:4154–4159. 246. Yousef A, Clark J, Doi SA 2010 Thyroxine suppression therapy for benign, non-functioning solitary thyroid nodules: a quality-effects meta-analysis. Clin Med Res 8:150–158.ATA THYROID NODULE/DTC GUIDELINES 101
247. Sdano MT, Falciglia M, Welge JA, Steward DL 2005 Efﬁcacy of thyroid hormone suppression for benign thyroid nodules: meta-analysis of randomized trials. Otolaryngol Head Neck Surg 133:391–396. 248. Grussendorf M, Reiners C, Paschke R, Wegscheider K 2011 Reduction of thyroid nodule volume by levothyr- oxine and iodine alone and in combination: a random- ized, placebo-controlled trial. J Clin Endocrinol Metab 96:2786–2795. 249. Puzziello A, Carrano M, Angrisani E, Marotta V, Fag- giano A, Zeppa P, Vitale M 2014 Evolution of benign thyroid nodules under levothyroxine non-suppressive therapy. J Endocrinol Invest 37:1181–1186. 250. Bennedbaek FN, Hegedus L 2003 Treatment of recurrent thyroid cysts with ethanol: a randomized double-blind controlled trial. J Clin Endocrinol Metab 88:5773–5777. 251. Valcavi R, Frasoldati A 2004 Ultrasound-guided percu- taneous ethanol injection therapy in thyroid cystic nod- ules. Endocr Pract 10:269–275. 252. Antonelli A, Campatelli A, Di VA, Alberti B, Baldi V, Salvioni G, Fallahi P,
Baschieri L 1994 Comparison between ethanol sclerotherapy and emptying with in- jection of saline in treatment of thyroid cysts. Clin In- vestig 72:971–974. 253. Verde G, Papini E, Pacella CM, Gallotti C, Delpiano S, Strada S, Fabbrini R, Bizzarri G, Rinaldi R, Panunzi C 1994 Ultrasound guided percutaneous ethanol injection in the treatment of cystic thyroid nodules. Clin En- docrinol (Oxf) 41:719–724. 254. Chen AY, Bernet VJ, Carty SE, Davies TF, Ganly I, Inabnet WB III, Shaha AR 2014 American Thyroid Association statement on optimal surgical management of goiter. Thyroid 24:181–189. 255. Shin JJ, Caragacianu D, Randolph GW 2015 Impact of thyroid nodule size on prevalence and post-test proba- bility of malignancy: a systematic review. Laryngoscope 125:263–272. 256. Marley EF, Oertel YC 1997 Fine-needle aspiration of thyroid lesions in 57 pregnant and postpartum women. Diagn Cytopathol 16:122–125. 257. Kung AW, Chau MT, Lao TT, Tam SC, Low LC 2002 The
effect of pregnancy on thyroid nodule formation. J Clin Endocrinol Metab 87:1010–1014. 258. Moosa M, Mazzaferri EL 1997 Outcome of differenti- ated thyroid cancer diagnosed in pregnant women. J Clin Endocrinol Metab 82:2862–2866. 259. Rosen IB, Korman M, Walﬁsh PG 1997 Thyroid nodular disease in pregnancy: current diagnosis and manage- ment. Clin Obstet Gynecol 40:81–89. 260. McLeod DS, Watters KF, Carpenter AD, Ladenson PW, Cooper DS, Ding EL 2012 Thyrotropin and thyroid cancer diagnosis: a systematic review and dose- response meta-analysis. J Clin Endocrinol Metab 97: 2682–2692. 261. Karger S, Schotz S, Stumvoll M, Berger F, Fuhrer D 2010 Impact of pregnancy on prevalence of goitre and nodular thyroid disease in women living in a region of borderline sufﬁcient iodine supply. Horm Metab Res 42: 137–142. 262. Messuti I, Corvisieri S, Bardesono F, Rapa I, Giorcelli J, Pellerito R, Volante M, Orlandi F 2014 Impact of pregnancy on prognosis of
differentiated thyroid cancer: clinical and molecular features. Eur J Endocrinol 170: 659–666.263. Vannucchi G, Perrino M, Rossi S, Colombo C, Vicentini L, Dazzi D, Beck-Peccoz P, Fugazzola L 2010 Clinical and molecular features of differentiated thyroid cancer diag- nosed during pregnancy. Eur J Endocrinol 162:145–151. 264. Mestman JH, Goodwin TM, Montoro MM 1995 Thyroid disorders of pregnancy. Endocrinol Metab Clin North Am24:41–71. 265. Herzon FS, Morris DM, Segal MN, Rauch G, Parnell T 1994 Coexistent thyroid cancer and pregnancy. Arch Otolaryngol Head Neck Surg 120:1191–1193. 266. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418–428. 267. Kuy S, Roman SA, Desai R, Sosa JA 2009 Outcomes following thyroid and parathyroid surgery in pregnant women. Arch Surg 144:399–406. 268. Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS 2011 Thyroid cancer incidence patterns in the United States by
histologic type, 1992–2006. Thyroid 21:125–134. 269. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985– 1995 [see commetns]. Cancer 83:2638–2648. 270. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS 1993 Predicting outcome in papillary thyroid carci- noma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114: 1050–1057. 271. Shah MD, Hall FT, Eski SJ, Witterick IJ, Walﬁsh PG, Freeman JL 2003 Clinical course of thyroid carcinoma after neck dissection. Laryngoscope 113:2102–2107. 272. Wang TS, Dubner S, Sznyter LA, Heller KS 2004 In- cidence of metastatic well-differentiated thyroid cancer in cervical lymph nodes. Arch Otolaryngol Head Neck Surg 130:110–113. 273. Mazzaferri EL 1999 An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 9:421–427. 274.
Mazzaferri EL 2000 Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. En- docr Pract 6:469–476. 275. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon HR III 1998 Thyrotropin suppression and disease pro-gression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8:737–744. 276. Lin JD, Chao TC, Huang MJ, Weng HF, Tzen KY 1998 Use of radioactive iodine for thyroid remnant ablation in well-differentiated thyroid carcinoma to replace thyroid reoperation. Am J Clin Oncol 21:77–81. 277. Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O’Sullivan B 1997 A comparison of different staging systems predictability of patient outcome. Thy- roid carcinoma as an example. Cancer 79:2414–2423. 278. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer
MS, McIver B, Mullan BP, Oberg AL, Powell CC, van Heerden JA, Goellner JR 2002 Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 con- secutively treated patients. World J Surg 26:879–885.102 HAUGEN ET AL.
279. Gourin CG, Tufano RP, Forastiere AA, Koch WM, Pawlik TM, Bristow RE 2010 Volume-based trends in thyroid surgery. Arch Otolaryngol Head Neck Surg 136:1191–1198. 280. Stavrakis AI, Ituarte PH, Ko CY, Yeh MW 2007 Surgeon volume as a predictor of outcomes in inpatient and out- patient endocrine surgery. Surgery 142:887–899. 281. Grebe SK, Hay ID 1996 Thyroid cancer nodal metasta- ses: biologic signiﬁcance and therapeutic considerations. Surg Oncol Clin N Am 5:43–63. 282. Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Dralle H 1994 Prognostic signiﬁcance and surgical management of locoregional lymph node metastases inpapillary thyroid cancer. World J Surg 18:559–567. 283. Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Ko- bayashi K, Yokozawa T, Matsuzuka F, Kuma S, Kuma K, Miyauchi A 2003 An observation trial without sur- gical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13:381–387. 284. Hay ID, Grant CS, van
Heerden JA, Goellner JR, Eber- sold JR, Bergstralh EJ 1992 Papillary thyroid micro- carcinoma: a study of 535 cases observed in a 50-year period. Surgery 112:1139–1146. 285. Qubain SW, Nakano S, Baba M, Takao S, Aikou T 2002 Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. Surgery 131:249– 256. 286. Arturi F, Russo D, Giuffrida D, Ippo lito A, Perrotti N, Vigneri R, Filetti S 1997 Early diagnosis by genetic anal- ysis of differentiated thyroid cancer metastases in small lymph nodes. J Clin Endocrinol Metab 82:1638–1641. 287. Solorzano CC, Carneiro DM, Ramirez M, Lee TM, Irvin GL, III 2004 Surgeon-performed ultrasound in the man- agement of thyroid malignancy. Am Surg 70:576–580. 288. Shimamoto K, Satake H, Sawaki A, Ishigaki T, Funa- hashi H, Imai T 1998 Preoperative staging of thyroid papillary carcinoma with ultrasonography. Eur J Radiol 29:4–10. 289. Stulak JM, Grant CS, Farley DR, Thompson GB, van
Heerden JA, Hay ID, Reading CC, Charboneau JW 2006 Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg 141:489–494. 290. Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken- Monro BS, Sherman SI, Vassilopoulou-Sellin R, Lee JE, Evans DB 2003 Role of preoperative ultrasonography inthe surgical management of patients with thyroid cancer. Surgery 134:946–954. 291. O’Connell K, Yen TW, Quiroz F, Evans DB, Wang TS 2013 The utility of routine preoperative cervical ultra- sonography in patients undergoing thyroidectomy for differentiated thyroid cancer. Surgery 154:697–701. 292. Leboulleux S, Girard E, Rose M, Travagli JP, Sabbah N, Caillou B, Hartl DM, Lassau N, Baudin E, Schlumberger M 2007 Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab 92:3590–3594. 293. Frasoldati A, Valcavi R 2004 Challenges in neck ultra- sonography: lymphadenopathy and parathyroid glands. Endocr Pract
10:261–268. 294. Kuna SK, Bracic I, Tesic V, Kuna K, Herceg GH, Dodig D 2006 Ultrasonographic differentiation of benign from malignant neck lymphadenopathy in thyroid cancer. J Ultrasound Med 25:1531–1537.295. Park JH, Lee YS, Kim BW, Chang HS, Park CS 2012 Skip lateral neck node metastases in papillary thyroid carcinoma. World J Surg 36:743–747. 296. Snozek CL, Chambers EP, Reading CC, Sebo TJ, Sis- trunk JW, Singh RJ, Grebe SK 2007 Serum thyroglob- ulin, high-resolution ultrasound, and lymph node thyroglobulin in diagnosis of differentiated thyroid car-cinoma nodal metastases. J Clin Endocrinol Metab 92: 4278–4281. 297. Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R 2003 Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 97:90–96. 298. Boi F, Baghino G, Atzeni F, Lai ML, Faa G, Mariotti S 2006 The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measure- ment in washout ﬂuid
from ﬁne-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. J Clin Endocrinol Metab 91:1364–1369. 299. Jeon MJ, Park JW, Han JM, Yim JH, Song DE, Gong G, Kim TY, Baek JH, Lee JH, Shong YK, Kim WB 2013 Serum antithyroglobulin antibodies interfere with thy- roglobulin detection in ﬁne-needle aspirates of metastatic neck nodes in papillary thyroid carcinoma. J Clin En- docrinol Metab 98:153–160. 300. Chung J, Kim EK, Lim H, Son EJ, Yoon JH, Youk JH, Kim JA, Moon HJ, Kwak JY 2014 Optimal indication of thyroglobulin measurement in ﬁne-needle aspiration for detecting lateral metastatic lymph nodes in patients with papillary thyroid carcinoma. Head Neck 36:795–801. 301. Grani G, Fumarola A 2014 Thyroglobulin in lymph node ﬁne-needle aspiration wash-out: a systematic review and meta-analysis of diagnostic accuracy. J Clin Endocrinol Metab 99:1970–1982. 302. Pak K, Suh S, Hong H, Cheon GJ, Hahn
SK, Kang KW, Kim EE, Lee DS, Chung JK 2015 Diagnostic values of thyroglobulin measurement in ﬁne-needle aspiration of lymph nodes in patients with thyroid cancer. Endocrine 49:70–77. 303. Pacini F, Fugazzola L, Lippi F, Ceccarelli C, Centoni R, Miccoli P, Elisei R, Pinchera A 1992 Detection of thy- roglobulin in ﬁne needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. J Clin Endocrinol Metab 74:1401–1404. 304. Moon JH, Kim YI, Lim JA, Choi HS, Cho SW, Kim KW, Park HJ, Paeng JC, Park YJ, Yi KH, Park do J, Kim SE, Chung JK 2013 Thyroglobulin in washout ﬂuid from lymph node ﬁne-needle aspiration biopsy in papillary thyroid cancer: large-scale validation of the cutoff value to determine malignancy and evaluation of discrepant results. J Clin Endocrinol Metab 98:1061–1068. 305. Giovanella L, Bongiovanni M, Trimboli P 2013 Diag- nostic value of thyroglobulin assay in
cervical lymph node ﬁne-needle aspirations for metastatic differentiated thyroid cancer. Curr Opin Oncol 25:6–13. 306. Stephenson BM, Wheeler MH, Clark OH 1994 The role of total thyroidectomy in the management of differenti- ated thyroid cancer. Curr Opin Gen Surg 2:53–59. 307. Ahn JE, Lee JH, Yi JS, Shong YK, Hong SJ, Lee DH, Choi CG, Kim SJ 2008 Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer. World J Surg 32: 1552–1558.ATA THYROID NODULE/DTC GUIDELINES 103
308. Choi JS, Kim J, Kwak JY, Kim MJ, Chang HS, Kim EK 2009 Preoperative staging of papillary thyroid carcino- ma: comparison of ultrasound imaging and CT. AJR Am J Roentgenol 193:871–878. 309. Lesnik D, Cunnane ME, Zurakowski D, Acar GO, Ecevit C, Mace A, Kamani D, Randolph GW 2014 Papillary thyroid carcinoma nodal surgery directed by a preoperative radiographic map utilizing CT scan and ultrasound in all primary and reoperative patients. Head Neck 36:191–202. 310. Jeong HS, Baek CH, Son YI, Choi JY, Kim HJ, Ko YH, Chung JH, Baek HJ 2006 Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ul-trasound and contrast-enhanced CT. Clin Endocrinol (Oxf) 65:402–407. 311. Kaplan SL, Mandel SJ, Muller R, Baloch ZW, Thaler ER, Loevner LA 2009 The role of MR imaging in detecting nodal disease in thyroidectomy patients with rising thy- roglobulin
levels. AJNR Am J Neuroradiol 30:608–612. 312. Andersen PE, Kinsella J, Loree TR, Shaha AR, Shah JP 1995 Differentiated carcinoma of the thyroid with ex- trathyroidal extension. Am J Surg 170:467–470. 313. Kim E, Park JS, Son KR, Kim JH, Jeon SJ, Na DG 2008 Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultra- sound with computed tomography. Thyroid 18:411–418. 314. Yeh MW, Bauer AJ, Bernet VA, Ferris RL, Loevner LA, Mandel SJ, Orloff LA, Randolph GW, Steward DL 2015 American Thyroid Association statement on preoperative imaging for thyroid cancer surgery. Thyroid 25:3–14. 315. Padovani RP, Kasamatsu TS, Nakabashi CC, Camacho CP, Andreoni DM, Malouf EZ, Marone MM, Maciel RM, Biscolla RP 2012 One month is sufﬁcient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post- thyroidectomy patients requiring radioiodine
therapy. Thyroid 22:926–930. 316. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS 2005 Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the man- agement of patients with differentiated thyroid carcino- mas. J Clin Endocrinol Metab 90:5566–5575. 317. McLeod DS, Cooper DS, Ladenson PW, Ain KB, Brierley JD, Fein HG, Haugen BR, Jonklaas J, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sher-man SI; for the National Thyroid Cancer Treatment Cooperative Study Group 2014 Prognosis of differenti- ated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thy- roid24:35–42. 318. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Win- chester DP, Talamonti MS, Sturgeon C 2007 Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 246:375–381. 319. Grant CS, Hay ID, Gough IR, Bergstralh EJ, Goellner JR, McConahey WM 1988 Local recurrence in papillary thyroid carcinoma:
is extent of surgical resection im- portant? Surgery 104:954–962. 320. Hay ID, Grant CS, Bergstralh EJ, Thompson GB, van Heerden JA, Goellner JR 1998 Unilateral total lobecto- my: is it sufﬁcient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 124:958–964.321. Mazzaferri EL, Kloos RT 2001 Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86: 1447–1463. 322. Matsuzu K, Sugino K, Masudo K, Nagahama M, Kita- gawa W, Shibuya H, Ohkuwa K, Uruno T, Suzuki A, Magoshi S, Akaishi J, Masaki C, Kawano M, Suganuma N, Rino Y, Masuda M, Kameyama K, Takami H, Ito K 2014 Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg 38:68–79. 323. Barney BM, Hitchcock YJ, Sharma P, Shrieve DC, Tward JD 2011 Overall and cause-speciﬁc survival for patients undergoing lobectomy, near-total, or total thy- roidectomy
for differentiated thyroid cancer. Head Neck 33:645–649. 324. Mendelsohn AH, Elashoff DA, Abemayor E, St John MA 2010 Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg 136:1055–1061. 325. Haigh PI, Urbach DR, Rotstein LE 2005 Extent of thy- roidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann Surg Oncol 12:81–89. 326. Nixon IJ, Ganly I, Patel SG, Palmer FL, Whitcher MM, Tuttle RM, Shaha A, Shah JP 2012 Thyroid lobectomy for treatment of well differentiated intrathyroid malig- nancy. Surgery 151:571–579. 327. Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, Scheri R, Roman SA, Sosa JA 2014 Extent of sur- gery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg 260: 601–605. 328. Vaisman F, Shaha A, Fish S, Michael TR 2011 Initial therapy with either thyroid lobectomy
or total thyroid- ectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease re- currence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol (Oxf) 75:112–119. 329. Tuggle CT, Roman S, Udelsman R, Sosa JA 2011 Same- day thyroidectomy: a review of practice patterns and outcomes for 1,168 procedures in New York State. Ann Surg Oncol 18:1035–1040. 330. Tuggle CT, Roman SA, Wang TS, Boudourakis L, Thomas DC, Udelsman R, Ann SJ 2008 Pediatric en- docrine surgery: who is operating on our children? Sur-gery 144:869–877. 331. Kandil E, Noureldine SI, Abbas A, Tufano RP 2013 The impact of surgical volume on patient outcomes following thyroid surgery. Surgery 154:1346–1352. 332. Duclos A, Peix JL, Colin C, Kraimps JL, Menegaux F, Pattou F, Sebag F, Touzet S, Bourdy S, Voirin N, Lifante JC 2012 Inﬂuence of experience on performance of in- dividual surgeons in thyroid surgery:
prospective cross sectional multicentre study. BMJ 344:d8041. 333. Hauch A, Al-Qurayshi Z, Randolph G, Kandil E 2014 Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol 21:3844–3852. 334. Hughes DT, White ML, Miller BS, Gauger PG, Burney RE, Doherty GM 2010 Inﬂuence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery 148:1100–1106.104 HAUGEN ET AL.
335. Randolph GW, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, Tufano RP, Tuttle RM 2012 The prognostic signiﬁcance of nodal metastases from papil- lary thyroid carcinoma can be stratiﬁed based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 22:1144– 1152. 336. Podnos YD, Smith D, Wagman LD, Ellenhorn JD 2005 The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg 71:731–734. 337. Zaydfudim V, Feurer ID, Grifﬁn MR, Phay JE 2008 The impact of lymph node involvement on survival in pa-tients with papillary and follicular thyroid carcinoma. Surgery 144:1070–1077. 338. Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM, Travagli JP, Schlumberger M 2005 Prog- nostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node me- tastases and/or tumor extension beyond the thyroid
capsule at initial diagnosis. J Clin Endocrinol Metab 90:5723–5729. 339. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A 2004 A novel classiﬁcation system for patients with PTC: addi- tion of the new variables of large (3 cm or greater) nodal metastases and reclassiﬁcation during the follow-up pe- riod. Surgery 135:139–148. 340. Adam MA, Pura J, Goffredo P, Dinan MA, Reed SD, Scheri RP, Hyslop T, Roman SA, Sosa JA 2015 Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J Clin Oncol 33: 2370–2375. 341. Robbins KT, Shaha AR, Medina JE, Califano JA, Wolf GT, Ferlito A, Som PM, Day TA 2008 Consensus statement on the classiﬁcation and terminology of neck dissection. Arch Otolaryngol Head Neck Surg 134: 536–538. 342. Hwang HS, Orloff LA 2011 Efﬁcacy of preoperative neck ultrasound in the detection of cervical lymph
node metastasis from thyroid cancer. Laryngoscope 121: 487–491. 343. Mulla M, Schulte KM 2012 Central cervical lymph node metastases in papillary thyroid cancer: a systematic re- view of imaging-guided and prophylactic removal of the central compartment. Clin Endocrinol (Oxf) 76:131–136. 344. Hartl DM, Leboulleux S, Al Ghuzlan A, Baudin E, Chami L, Schlumberger M, Travagli JP 2012 Optimi- zation of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carci- noma. Ann Surg 255:777–783. 345. Popadich A, Levin O, Lee JC, Smooke-Praw S, Ro K, Fazel M, Arora A, Tolley NS, Palazzo F, Learoyd DL, Sidhu S, Delbridge L, Sywak M, Yeh MW 2011 A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery 150:1048–1057. 346. Lang BH, Wong KP, Wan KY, Lo CY 2012 Impact of routine unilateral central neck dissection on preablative and postablative
stimulated thyroglobulin levels after total thyroidectomy in papillary thyroid carcinoma. Ann Surg Oncol 19:60–67. 347. Wang TS, Evans DB, Fareau GG, Carroll T, Yen TW 2012 Effect of prophylactic central compartment neckdissection on serum thyroglobulin and recommendations for adjuvant radioactive iodine in patients with differ- entiated thyroid cancer. Ann Surg Oncol 19:4217–4222. 348. Carty SE, Cooper DS, Doherty GM, Duh QY, Kloos RT, Mandel SJ, Randolph GW, Stack BC Jr, Steward DL, Terris DJ, Thompson GB, Tufano RP, Tuttle RM, Udelsman R 2009 Consensus statement on the termi- nology and classiﬁcation of central neck dissection for thyroid cancer. Thyroid 19:1153–1158. 349. Chisholm EJ, Kulinskaya E, Tolley NS 2009 Systematic review and meta-analysis of the adverse effects of thy- roidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope119:1135–1139. 350. Bonnet S, Hartl D, Leboulleux S, Baudin E, Lumbroso JD, Al Ghuzlan A, Chami L, Schlumberger M, TravagliJP 2009
Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radio- iodine treatment. J Clin Endocrinol Metab 94:1162– 1167. 351. Sancho JJ, Lennard TW, Paunovic I, Triponez F, Sitges- Serra A 2014 Prophylactic central neck disection in papillary thyroid cancer: a consensus report of the Eu- ropean Society of Endocrine Surgeons (ESES). Lan- genbecks Arch Surg 399:155–163. 352. Zetoune T, Keutgen X, Buitrago D, Aldailami H, Shao H, Mazumdar M, Fahey TJ III, Zarnegar R 2010 Pro- phylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis. Ann Surg Oncol 17:3287–3293. 353. Barczynski M, Konturek A, Stopa M, Nowak W 2013 Prophylactic central neck dissection for papillary thyroid cancer. Br J Surg 100:410–418. 354. Hartl DM, Mamelle E, Borget I, Leboulleux S, Mirghani H, Schlumberger M 2013 Inﬂuence of prophylactic neck dissection on rate of retreatment for papillary thyroid carcinoma. World J Surg
37:1951–1958. 355. Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L 2006 Routine ipsilateral level VI lympha- denectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery 140:1000–1005. 356. Laird AM, Gauger PG, Miller BS, Doherty GM 2012 Evaluation of postoperative radioactive iodine scans in patients who underwent prophylactic central lymph node dissection. World J Surg 36:1268–1273. 357. Costa S, Giugliano G, Santoro L, Ywata De Carvalho A, Massaro MA, Gibelli B, De Fiori E, Grosso E, Ansarin M, Calabrese L 2009 Role of prophylactic central neck dissection in cN0 papillary thyroid cancer. Acta Otor- hinolaryngol Ital 29:61–69. 358. Ryu IS, Song CI, Choi SH, Roh JL, Nam SY, Kim SY 2014 Lymph node ratio of the central compartment is a signiﬁcant predictor for locoregional recurrence after prophylactic central neck dissection in patients with thy- roid papillary carcinoma. Ann Surg Oncol 21:277–283. 359. Moreno MA, Edeiken-Monroe BS,
Siegel ER, Sherman SI, Clayman GL 2012 In papillary thyroid cancer, pre- operative central neck ultrasound detects only macro- scopic surgical disease, but negative ﬁndings predict excellent long-term regional control and survival. Thy- roid22:347–355. 360. Yoo D, Ajmal S, Gowda S, Machan J, Monchik J, Mazzaglia P 2012 Level VI lymph node dissection does not decrease radioiodine uptake in patients undergoingATA THYROID NODULE/DTC GUIDELINES 105
radioiodine ablation for differentiated thyroid cancer. World J Surg 36:1255–1261. 361. Roh JL, Park JY, Park CI 2007 Total thyroidectomy plus neck dissection in differentiated papillary thyroid carci- noma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathy- roid hormone. Ann Surg 245:604–610. 362. Cavicchi O, Piccin O, Caliceti U, De Cataldis A, Pas- quali R, Ceroni AR 2007 Transient hypoparathyroidism following thyroidectomy: a prospective study and mul- tivariate analysis of 604 consecutive patients. Otolar- yngol Head Neck Surg 137:654–658. 363. Raffaelli M, De Crea C, Sessa L, Giust acchini P, Revelli L, Bellantone C, Lombardi CP 2012 Prospective evaluation of total thyroidectomy versus ipsil ateral versus bilateral central neck dissection in patients wit h clinically node-negative papillary thyroid carcinoma. Surgery 152:957–964. 364. Viola D, Materazzi G, Valerio L, Molinaro E, Agate L, Faviana P, Seccia V, Sensi E, Romei C, Piaggi P, Tor- regrossa L,
Sellari-Franceschini S, Basolo F, Vitti P, Elisei R, Miccoli P 2015 Prophylactic central compart- ment lymph node dissection in papillary thyroid carci- noma: clinical implications derived from the ﬁrst prospective randomized controlled single institution study. J Clin Endocrinol Metab 100:1316–1324. 365. Lang BH, Ng SH, Lau LL, Cowling BJ, Wong KP, Wan KY 2013 A systematic review and meta-analysis of pro- phylactic central neck dissection on short-term loco- regional recurrence in papillary thyroid carcinoma after total thyroidectomy. Thyroid 23:1087–1098. 366. Wang TS, Cheung K, Farrokhyar F, Roman SA, Sosa JA 2013 A meta-analysis of the effect of prophylactic cen- tral compartment neck dissection on locoregional recur- rence rates in patients with papillary thyroid cancer. Ann Surg Oncol 20:3477–3483. 367. Gyorki DE, Untch B, Tuttle RM, Shaha AR 2013 Pro- phylactic central neck dissection in differentiated thyroid cancer: an assessment of the evidence. Ann Surg Oncol 20:2285–2289. 368. Haymart MR, Banerjee
M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ 2011 Use of radioactive iodine for thyroid cancer. JAMA 306:721–728. 369. Howell GM, Nikiforova MN, Carty SE, Armstrong MJ, Hodak SP, Stang MT, McCoy KL, Nikiforov YE, Yip L 2013 BRAFV600Emutation independently predicts central compartment lymph node metastasis in patients withpapillary thyroid cancer. Ann Surg Oncol 20:47–52. 370. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O’Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V 2013 Association between BRAFV600Emutation and mortality in patients with papillary thyroid cancer. JAMA 309:1493–1501. 371. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK,
Youn YK, Kim KH, Cho BY, Park do J 2012 The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118:1764–1773. 372. Ito Y, Yoshida H, Kihara M, Kobayashi K, Miya A, Miyauchi A 2014 BRAF(V600E) mutation analysis inpapillary thyroid carcinoma: is it useful for all patients? World J Surg 38:679–687. 373. Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A, Orloff LA 2013 Lack of association of BRAF muta- tion with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg 139:1164–1170. 374. Dutenhefner SE, Marui S, Santos AB, de Lima EU, In- oue M, Neto JS, Shiang C, Fukushima JT, Cernea CR, Friguglietti CU 2013 BRAF: a tool in the decision to perform elective neck dissection? Thyroid 23:1541– 1546. 375. Lee KC, Li C, Schneider EB, Wang
Y, Somervell H, Krafft M, Umbricht CB, Zeiger MA 2012 Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer? Surgery 152: 977–983. 376. Xing M 2010 Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 321: 86–93. 377. Sugitani I, Fujimoto Y, Yamada K, Yamamoto N 2008 Prospective outcomes of selective lymph node dissection for papillary thyroid carcinoma based on preoperative ultrasonography. World J Surg 32:2494–2502. 378. Ito Y, Miyauchi A 2007 Lateral and mediastinal lymph node dissection in differentiated thyroid carcinoma: in- dications, beneﬁts, and risks. World J Surg 31:905–915. 379. Gemsenjager E, Perren A, Seifert B, Schuler G, Schweizer I, Heitz PU 2003 Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg 197:182–190. 380. Kouvaraki MA, Lee JE, Shapiro SE, Sherman SI, Evans DB 2004 Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery 136: 1183–1191. 381.
Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Ko- bayashi K, Matsuzuka F, Kuma K, Miyauchi A 2004 Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid. World J Surg 28:498–501. 382. Erdem E, Gulcelik MA, Kuru B, Alagol H 2003 Com- parison of completion thyroidectomy and primary sur- gery for differentiated thyroid carcinoma. Eur J Surg Oncol 29:747–749. 383. Tan MP, Agarwal G, Reeve TS, Barraclough BH, Del- bridge LW 2002 Impact of timing on completion thy- roidectomy for thyroid cancer. Br J Surg 89:802–804. 384. Untch BR, Palmer FL, Ganly I, Patel SG, Michael TR, Shah JP, Shaha AA 2014 Oncologic outcomes af- ter completion thyroidectomy for patients with well- differentiated thyroid carcinoma. Ann Surg Oncol 21: 1374–1378. 385. Barbesino G, Goldfarb M, Parangi S, Yang J, Ross DS, Daniels GH 2012 Thyroid lobe ablation with
radioactive iodine as an alternative to completion thyroidectomy after hemithyroidectomy in patients with follicular thyroid carcinoma: long-term follow-up. Thyroid 22:369–376. 386. Santra A, Bal S, Mahargan S, Bal C 2011 Long-term outcome of lobar ablation versus completion thyroidec- tomy in differentiated thyroid cancer. Nucl Med Com- mun 32:52–58. 387. Giovanella L, Piccardo A, Paone G, Foppiani L, Treglia G, Ceriani L 2013 Thyroid lobe ablation with iodine-131I106 HAUGEN ET AL.
in patients with differentiated thyroid carcinoma: a ran- domized comparison between 1.1 and 3.7 GBq activities. Nucl Med Commun 34:767–770. 388. O’Connor AM, Bennett CL, Stacey D, Barry M, Col NF, Eden KB, Entwistle VA, Fiset V, Holmes-Rovner M, Khangura S, Llewellyn-Thomas H, Rovner D 2009 De- cision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev (3): CD001431. 389. Feldman-Stewart D, Capirci C, Brennenstuhl S, Tong C, Abacioglu U, Gawkowska-Suwinska M, van Gils F, Heyda A, Igdem S, Macias V, Grillo IM, Moynihan C, Pijls-Johannesma M, Parker C, Pimentel N, Wo ¨rdehoff H 2011 Information for decision making by patients with early-stage prostate cancer: a comparison across 9 countries. Med Decis Making 31:754–766. 390. Haynes RB, McKibbon KA, Kanani R 1996 Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 348:383–386. 391. Weiss SM, Wengert PA Jr, Martinez
EM, Sewall W, Kopp E 1996 Patient sati sfaction with decision- making for breast cancer therapy. Ann Surg Oncol 3:285–289. 392. Street RL Jr, Voigt B 1997 Patient participation in de- ciding breast cancer treatment and subsequent quality of life. Med Decis Making 17:298–306. 393. Abdul-Sater L, Henry M, Majdan A, Mijovic T, Franklin JH, Brandt MG, Black MJ, Hier MP, Payne RJ 2011 What are thyroidectomy patients really concerned about? Otolaryngol Head Neck Surg 144:685–690. 394. Husson O, Haak HR, Oranje WA, Mols F, Reemst PH, van de Poll-Franse LV 2011 Health-related quality of life among thyroid cancer survivors: a systematic review. Clin Endocrinol (Oxf) 75:544–554. 395. Stojadinovic A, Shaha AR, Orlikoff RF, Nissan A, Kornak MF, Singh B, Boyle JO, Shah JP, Brennan MF, Kraus DH 2002 Prospective functional voice assessment in patients undergoing thyroid surgery. Ann Surg 236: 823–832. 396. Soylu L, Ozbas S, Uslu HY, Kocak
S 2007 The evalu- ation of the causes of subjective voice disturbances after thyroid surgery. Am J Surg 194:317–322. 397. Wilson JA, Deary IJ, Millar A, Mackenzie K 2002 The quality of life impact of dysphonia. Clin Otolaryngol Allied Sci 27:179–182. 398. Jones SM, Carding PN, Drinnan MJ 2006 Exploring the relationship between severity of dysphonia and voice- related quality of life. Clin Otolaryngol 31:411–417. 399. Munch S, deKryger L 2001 A piece of my mind. Moral wounds: complicated complications. JAMA 285:1131– 1132. 400. Cohen SM, Kim J, Roy N, Asche C, Courey M 2012 Prevalence and causes of dysphonia in a large treatment- seeking population. Laryngoscope 122:343–348. 401. Singer MC, Iverson KC, Terris DJ 2012 Thyroidectomy- related malpractice claims. Otolaryngol Head Neck Surg 146:358–361. 402. Chandrasekhar SS, Randolph GW, Seidman MD, Rosenfeld RM, Angelos P, Barkmeier-Kraemer J, Ben- ninger MS, Blumin JH, Dennis G, Hanks J, Haymart MR, Kloos
RT, Seals B, Schreibstein JM, Thomas MA, Waddington C, Warren B, Robertson PJ 2013 Clinical practice guideline: improving voice outcomesafter thyroid surgery. Otolaryngol Head Neck Surg 148: S1–37. 403. Farrag TY, Samlan RA, Lin FR, Tufano RP 2006 The utility of evaluating true vocal fold motion before thyroid surgery. Laryngoscope 116:235–238. 404. Roh JL, Yoon YH, Park CI 2009 Recurrent laryngeal nerve paralysis in patients with papillary thyroid carci-nomas: evaluation and management of resulting vocal dysfunction. Am J Surg 197:459–465. 405. Randolph GW, Kamani D 2006 The importance of pre- operative laryngoscopy in patients undergoing thyroid- ectomy: voice, vocal cord function, and the preoperative detection of invasive thyroid malignancy. Surgery 139: 357–362. 406. Eadie TL, Kapsner M, Rosenzweig J, Waugh P, Hillel A, Merati A 2010 The role of experience on judgments of dysphonia. J Voice 24:564–573. 407. Rowe-Jones JM, Rosswick RP, Leighton SE 1993 Be- nign thyroid disease and
vocal cord palsy. Ann R Coll Surg Engl 75:241–244. 408. Shin JJ, Grillo HC, Mathisen D, Katlic MR, Zurakowski D, Kamani D, Randolph GW 2011 The surgical man- agement of goiter: Part I. Preoperative evaluation. Lar- yngoscope 121:60–67. 409. Bergenfelz A, Jansson S, Kristoffersson A, Martensson H, Reihner E, Wallin G, Lausen I 2008 Complications to thyroid surgery: results as reported in a database from a multicenter audit comprising 3,660 patients. Langen- becks Arch Surg 393:667–673. 410. Green KM, de Carpentier JP 1999 Are pre-operative vocal fold checks necessary? J Laryngol Otol 113:642– 644. 411. Cheng SP, Lee JJ, Liu TP, Lee KS, Liu CL 2012 Pre- operative ultrasonography assessment of vocal cord movement during thyroid and parathyroid surgery. World J Surg 36:2509–2515. 412. Terris DJ, Snyder S, Carneiro-Pla D, Inabnet WB III, Kandil E, Orloff L, Shindo M, Tufano RP, Tuttle RM, Urken M, Yeh MW 2013 American Thyroid
Association statement on outpatient thyroidectomy. Thyroid 23: 1193–1202. 413. Dralle H, Sekulla C, Haerting J, Timmermann W, Neu- mann HJ, Kruse E, Grond S, Muhlig HP, Richter C, Voss J, Thomusch O, Lippert H, Gastinger I, Brauckhoff M, Gimm O 2004 Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring inthyroid surgery. Surgery 136:1310–1322. 414. Shindo ML, Caruana S, Kandil E, McCaffrey JC, Orloff L, Porterﬁeld JR, Randolph G, Shaha A, Shin J, Terris D 2014 Management of invasive well-differentiated thyroid cancer an American Head and Neck Society consensus statement. Head Neck 36:1379–1390. 415. Falk SA, McCaffrey TV 1995 Management of the re- current laryngeal nerve in suspected and proven thyroid cancer. Otolaryngol Head Neck Surg 113:42–48. 416. Jatzko GR, Lisborg PH, Muller MG, Wette VM 1994 Recurrent nerve palsy after thyroid operations—principal nerve identiﬁcation and a literature review. Surgery 115:139–144. 417. Lo CY, Kwok KF, Yuen
PW 2000 A prospective eval- uation of recurrent laryngeal nerve paralysis during thyroidectomy. Arch Surg 135:204–207. 418. Curran AJ, Smyth D, Sheehan SJ, Joyce W, Hayes DB, Walsh MA 1997 Recurrent laryngeal nerve dysfunctionATA THYROID NODULE/DTC GUIDELINES 107
following carotid endarterectomy. J R Coll Surg Edinb 42:168–170. 419. Rosenthal LH, Benninger MS, Deeb RH 2007 Vocal fold immobility: a longitudinal analysis of etiology over 20 years. Laryngoscope 117:1864–1870. 420. Kriskovich MD, Apfelbaum RI, Haller JR 2000 Vocal fold paralysis after anterior cervical spine surgery: inci- dence, mechanism, and prevention of injury. Laryngo- scope 110:1467–1473. 421. Benninger MS, Crumley RL, Ford CN, Gould WJ, Hanson DG, Ossoff RH, Sataloff RT 1994 Evaluation and treatment of the unilateral paralyzed vocal fold. Otolaryngol Head Neck Surg 111:497–508. 422. Grundfast KM, Harley E 1989 Vocal cord paralysis. Otolaryngol Clin North Am 22:569–597. 423. Hermann M, Alk G, Roka R, Glaser K, Freissmuth M 2002 Laryngeal recurrent nerve injury in surgery for benign thyroid diseases: effect of nerve dissection and impact of individual surgeon in more than 27,000 nerves at risk. Ann Surg 235:261–268. 424. Randolph GW, Dralle H, Abdullah H, Barczynski M,
Bellantone R, Brauckhoff M, Carnaille B, Cherenko S, Chiang FY, Dionigi G, Finck C, Hartl D, Kamani D, Lorenz K, Miccolli P, Mihai R, Miyauchi A, Orloff L, Perrier N, Poveda MD, Romanchishen A, Serpell J, Sitges-Serra A, Sloan T, Van SS, Snyder S, Takami H, Volpi E, Woodson G 2011 Electrophysiologic recurrent laryngeal nerve monitoring during thyroid and parathyroid surgery: international standards guideline statement. Laryngoscope 121(Suppl 1): S1– S16. 425. Pisanu A, Porceddu G, Podda M, Cois A, Uccheddu A 2014 Systematic review with meta-analysis of studies comparing intraoperative neuromonitoring of recurrent laryngeal nerves versus visualization alone during thy- roidectomy. J Surg Res 188:152–161. 426. Barczynski M, Konturek A, Stopa M, Honowska A, Nowak W 2012 Randomized controlled trial of visuali- zation versus neuromonitoring of the external branch of the superior laryngeal nerve during thyroidectomy. World J Surg 36:1340–1347. 427. Chan WF, Lang BH, Lo CY 2006 The role
of in- traoperative neuromonitoring of recurrent laryngeal nerve during thyroidectomy: a comparative study on 1000 nerves at risk. Surgery 140:866–872. 428. Musholt TJ, Clerici T, Dralle H, Frilling A, Goretzki PE, Hermann MM, Kussmann J, Lorenz K, Nies C, Schab- ram J, Schabram P, Scheuba C, Simon D, Steinmuller T, Trupka AW, Wahl RA, Zielke A, Bockisch A, Karges W, Luster M, Schmid KW 2011 German Association of Endocrine Surgeons practice guidelines for the surgical treatment of benign thyroid disease. Langenbecks Arch Surg 396:639–649. 429. Sturgeon C, Sturgeon T, Angelos P 2009 Neuromoni- toring in thyroid surgery: attitudes, usage patterns, and predictors of use among endocrine surgeons. World J Surg 33:417–425. 430. Horne SK, Gal TJ, Brennan JA 2007 Prevalence and patterns of intraoperative nerve monitoring for thyroid- ectomy. Otolaryngol Head Neck Surg 136:952–956. 431. Sadowski SM, Soardo P, Leuchter I, Robert JH, Triponez F 2013 Systematic use of recurrent
laryngeal nerve neuromonitoring changes the operative strategy in plan- ned bilateral thyroidectomy. Thyroid 23:329–333.432. Goretzki PE, Schwarz K, Brinkmann J, Wirowski D, Lammers BJ 2010 The impact of intraoperative neuro- monitoring (IONM) on surgical strategy in bilateral thyroid diseases: is it worth the effort? World J Surg 34:1274–1284. 433. Melin M, Schwarz K, Lammers BJ, Goretzki PE 2013 IONM-guided goiter surgery leading to two-stage thy- roidectomy—indication and results. Langenbecks ArchSurg 398:411–418. 434. Barczynski M, Randolph GW, Cernea CR, Dralle H, Dionigi G, Alesina PF, Mihai R, Finck C, Lombardi D, Hartl DM, Miyauchi A, Serpell J, Snyder S, Volpi E, Woodson G, Kraimps JL, Hisham AN 2013 Externalbranch of the superior laryngeal nerve monitoring during thyroid and parathyroid surgery: International Neural Monitoring Study Group standards guideline statement. Laryngoscope 123(Suppl 4): S1–S14. 435. Randolph GW, Clark OH 2013 Principles in thyroid surgery. In: Randolph GW (ed) Surgery of the Thyroid and
Parathyroid Glands. 2nd edition. Elsevier, Philadel- phia, PA, pp 273–293. 436. Lorente-Poch L, Sancho JJ, Ruiz S, Sitges-Serra A 2015 Importance of in situ preservation of parathyroid glands during total thyroidectomy. Br J Surg 102:359–367. 437. Friedman AD, Burns JA, Heaton JT, Zeitels SM 2010 Early versus late injection medialization for unilateral vocal cord paralysis. Laryngoscope 120:2042–2046. 438. Arviso LC, Johns MM III, Mathison CC, Klein AM 2010 Long-term outcomes of injection laryngoplasty in pa- tients with potentially recoverable vocal fold paralysis. Laryngoscope 120:2237–2240. 439. Yung KC, Likhterov I, Courey MS 2011 Effect of tem- porary vocal fold injection medialization on the rate of permanent medialization laryngoplasty in unilateral vocal fold paralysis patients. Laryngoscope 121:2191–2194. 440. Carty SE, Doherty GM, Inabnet WB III, Pasieka JL, Randolph GW, Shaha AR, Terris DJ, Tufano RP, Tuttle RM 2012 American Thyroid Association statement on the essential elements of interdisciplinary communica- tion of perioperative
information for patients undergoing thyroid cancer surgery. Thyroid 22:395–399. 441. DeLellis RA, Lloyd RV, Heitz PU, Eng C 2004 World Health Organization Classiﬁcation of Tumours. Pathol- ogy and Genetics of Tumours of Endocrine Organs. IARC Press, Lyon. 442. Haigh PI, Urbach DR 2005 The treatment and prognosis of Hu ¨rthle cell follicular thyroid carcinoma compared with its non-Hu ¨rthle cell counterpart. Surgery 138:1152– 1157. 443. Shaha AR, Loree TR, Shah JP 1995 Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 118:1131–1136. 444. Ganly I, Ricarte FJ, Eng S, Ghossein R, Morris LG, Liang Y, Socci N, Kannan K, Mo Q, Fagin JA, Chan TA 2013 Genomic dissection of Hu ¨rthle cell carcinoma re- veals a unique class of thyroid malignancy. J Clin En- docrinol Metab 98:E962–E972. 445. Baloch ZW, LiVolsi VA 2002 Follicular-patterned le- sions of the thyroid: the bane of the pathologist. Am J
Clin Pathol 117:143–150. 446. D’Avanzo A, Treseler P, Ituarte PH, Wong M, Streja L, Greenspan FS, Siperstein AE, Duh QY, Clark OH 2004 Follicular thyroid carcinoma: histology and prognosis. Cancer 100:1123–1129.108 HAUGEN ET AL.
447. Rosai J 2005 Handling of thyroid follicular patterned lesions. Endocr Pathol 16:279–283. 448. Nikiforov YE, Ohori NP 2012 Follicular carcinoma. In: Nikiforov YE, Biddinger PW, Thompson LDR (eds) Di- agnostic Pathology and Molecular Genetics of the Thyroid. 1st edition. Lippincott, Philadelphia, PA, pp 152–182. 449. Yamashita H, Noguchi S, Murakami N, Kawamoto H, Watanabe S 1997 Extracapsular invasion of lymph node metastasis is an indicator of distant metastasis and poor prognosis in patients with thyroid papillary carcinoma. Cancer 80:2268–2272. 450. Lango M, Flieder D, Arrangoiz R, Veloski C, Yu JQ, Li T, Burtness B, Mehra R, Galloway T, Ridge JA 2013Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, no- dal persistence, and systemic disease progression. Thy- roid23:1099–1105. 451. Falvo L, Catania A, D’Andrea V, Marzullo A, Giusti- niani MC, De Antoni E 2005 Prognostic importance of histologic vascular invasion in papillary thyroid carci- noma. Ann Surg
241:640–646. 452. Gardner RE, Tuttle RM, Burman KD, Haddady S, Tru- man C, Sparling YH, Wartofsky L, Sessions RB, Ringel MD 2000 Prognostic importance of vascular invasion in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 126:309–312. 453. Mete O, Asa SL 2011 Pathological deﬁnition and clinical signiﬁcance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod Pathol 24:1545– 1552. 454. Brennan MD, Bergstralh EJ, van Heerden JA, McCo- nahey WM 1991 Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic ﬁndings, therapy, and outcome. Mayo Clin Proc 66:11–22. 455. Collini P, Sampietro G, Pilotti S 2004 Extensive vascular invasion is a marker of risk of relapse in encapsulated non-Hu ¨rthle cell follicular carcinoma of the thyroid gland: a clinicopathological study of 18 consecutive cases from a single institution with a 11-year median follow-up. Histopathology 44:35–39. 456. Lang W, Choritz H, Hundeshagen H
1986 Risk factors in follicular thyroid carcinomas. A retrospective follow-up study covering a 14-year period with emphasis on mor- phological ﬁndings. Am J Surg Pathol 10:246–255. 457. Nikiforov YE, Ohori NP 2012 Papillary carcinoma. In: Nikiforov YE, Biddinger PW, Thompson LDR (eds) Di- agnostic Pathology and Molecular Genetics of the Thyroid. 1st edition. Lippincott, Philadelphia, PA, pp 183–262. 458. Hawk WA, Hazard JB 1976 The many appearances of papillary carcinoma of the thyroid. Cleve Clin Q 43: 207–215. 459. Leung AK, Chow SM, Law SC 2008 Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma. Laryngoscope 118:32–38. 460. Moreno EA, Rodriguez Gonzalez JM, Sola PJ, Soria CT, Parrilla PP 1993 Prognostic value of the tall cell variety of papillary cancer of the thyroid. Eur J Surg Oncol 19: 517–521. 461. Ostrowski ML, Merino MJ 1996 Tall cell variant of papillary thyroid carcinoma: a reassessment and immu-
nohistochemical study with comparison to the usual type of papillary carcinoma of the thyroid. Am J Surg Pathol 20:964–974.462. Johnson TL, Lloyd RV, Thompson NW, Beierwaltes WH, Sisson JC 1988 Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol 12:22–27. 463. Michels JJ, Jacques M, Henry-Amar M, Bardet S 2007 Prevalence and prognostic signiﬁcance of tall cell variant of papillary thyroid carcinoma. Hum Pathol 38:212–219. 464. Ghossein RA, Leboeuf R, Patel KN, Rivera M, Katabi N, Carlson DL, Tallini G, Shaha A, Singh B, Tuttle RM 2007 Tall cell variant of papillary thyroid carcinomawithout extrathyroid extension: biologic behavior and clinical implications. Thyroid 17:655–661. 465. Morris LG, Shaha AR, Tuttle RM, Sikora AG, Ganly I 2010 Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid 20:153–158. 466. Xing M 2005 BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245–262. 467. Chen JH,
Faquin WC, Lloyd RV, Nose V 2011 Clin- icopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid car- cinoma. Mod Pathol 24:739–749. 468. Evans HL 1986 Columnar-cell carcinoma of the thyroid. A report of two cases of an aggressive variant of thyroid carcinoma. Am J Clin Pathol 85:77–80. 469. Evans HL 1996 Encapsulated columnar-cell neoplasms of the thyroid. A report of four cases suggesting a fa- vorable prognosis. Am J Surg Pathol 20:1205–1211. 470. Wenig BM, Thompson LD, Adair CF, Shmookler B, Heffess CS 1998 Thyroid papillary carcinoma of co- lumnar cell type: a clinicopathologic study of 16 cases. Cancer 82:740–753. 471. Asioli S, Erickson LA, Sebo TJ, Zhang J, Jin L, Thompson GB, Lloyd RV 2010 Papillary thyroid carci- noma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molec- ular study of eight cases. Am
J Surg Pathol 34:44–52. 472. Motosugi U, Murata S, Nagata K, Yasuda M, Shimizu M 2009 Thyroid papillary carcinoma with micropapillary and hobnail growth pattern: a histological variant with intermediate malignancy? Thyroid 19:535–537. 473. Lubitz CC, Economopoulos KP, Pawlak AC, Lynch K, Dias-Santagata D, Faquin WC, Sadow PM 2014 Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular proﬁle. Thyroid 24:958–965. 474. Mizukami Y, Noguchi M, Michigishi T, Nonomura A, Hashimoto T, Otakes S, Nakamura S, Matsubara F 1992 Papillary thyroid carcinoma in Kanazawa, Japan: prog- nostic signiﬁcance of histological subtypes. Histo- pathology 20:243–250. 475. Nikiforov YE, Erickson LA, Nikiforova MN, Caudill CM, Lloyd RV 2001 Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol 25:1478–1484. 476. Cardis E, Howe G, Ron E, Bebeshko V, Bogdanova T, Bouville A, Carr Z, Chumak V, Davis S, Demidchik Y, Drozdovitch
V, Gentner N, Gudzenko N, Hatch M, Ivanov V, Jacob P, Kapitonova E, Kenigsberg Y, Kes- miniene A, Kopecky KJ, Kryuchkov V, Loos A, Pinch- era A, Reiners C, Repacholi M, Shibata Y, Shore RE, Thomas G, Tirmarche M, Yamashita S, Zvonova I 2006 Cancer consequences of the Chernobyl accident: 20 years on. J Radiol Prot 26:127–140.ATA THYROID NODULE/DTC GUIDELINES 109
477. Nikiforov YE 2006 Radiation-induced thyroid cancer: what we have learned from Chernobyl. Endocr Pathol 17:307–317. 478. Volante M, Collini P, Nikiforov YE, Sakamoto A, Ka- kudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M, Bussolati G, Rosai J 2007 Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 31:1256–1264. 479. Asioli S, Erickson LA, Righi A, Jin L, Volante M, Jen- kins S, Papotti M, Bussolati G, Lloyd RV 2010 Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. ModPathol 23:1269–1278. 480. Fukushima M, Ito Y, Hirokawa M, Akasu H, Shimizu K, Miyauchi A 2009 Clinicopathologic characteristics and prognosis of diffuse sclerosing variant of papillary thy- roid carcinoma in Japan: an 18-year experience at a single institution. World J Surg 33:958–962. 481. Koo JS, Hong
S, Park CS 2009 Diffuse sclerosing variant is a major subtype of papillary thyroid carcinoma in the young. Thyroid 19:1225–1231. 482. Regalbuto C, Malandrino P, Tumminia A, Le Moli R, Vigneri R, Pezzino V 2011 A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases. Thyroid 21:383–389. 483. Lam AK, Lo CY 2006 Diffuse sclerosing variant of papillary carcinoma of the thyroid: a 35-year compara- tive study at a single institution. Ann Surg Oncol 13: 176–181. 484. Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, Fagin JA, Ghossein RA 2010 Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs inﬁltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 23:1191–1200. 485. Howitt BE, Jia Y, Sholl LM, Barletta JA 2013 Molecular alterations in partially-encapsulated or well-circumscribed follicular variant of papillary thyroid carcinoma. Thyroid 23:1256–1262.
486. Liu J, Singh B, Tallini G, Carlson DL, Katabi N, Shaha A, Tuttle RM, Ghossein RA 2006 Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer 107:1255–1264. 487. Piana S, Frasoldati A, Di Felice E, Gardini G, Tallini G, Rosai J 2010 Encapsulated well-differentiated follicular- patterned thyroid carcinomas do not play a signiﬁcant role in the fatality rates from thyroid carcinoma. Am J Surg Pathol 34:868–872. 488. Proietti A, Giannini R, Ugolini C, Miccoli M, Fontanini G, Di Coscio G, Romani R, Berti P, Miccoli P, Basolo F 2010 BRAF status of follicular variant of papillary thy- roid carcinoma and its relationship to its clinical and cytological features. Thyroid 20:1263–1270. 489. Chan J 2002 Strict criteria should be applied in the di- agnosis of encapsulated follicular variant of papillary thyroid carcinoma. Am J Clin Pathol 117:16–18. 490. Vivero M, Kraft S, Barletta JA 2013
Risk stratiﬁcation of follicular variant of papillary thyroid carcinoma. Thyroid 23:273–279. 491. Baloch ZW, LiVolsi VA 2000 Encapsulated follicular variant of papillary thyroid carcinoma with bone me- tastases. Mod Pathol 13:861–865.492. Hunt JL, Dacic S, Barnes EL, Bures JC 2002 En- capsulated follicular variant of papillary thyroid carci- noma. Am J Clin Pathol 118:602–603. 493. Rivera M, Ricarte-Filho J, Patel S, Tuttle M, Shaha A, Shah JP, Fagin JA, Ghossein RA 2010 Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopath- ologic and molecular study. Hum Pathol 41:172–180. 494. O’Neill CJ, Vaughan L, Learoyd DL, Sidhu SB, Del- bridge LW, Sywak MS 2011 Management of follicularthyroid carcinoma should be individualised based on degree of capsular and vascular invasion. Eur J Surg Oncol 37:181–185. 495. van Heerden JA, Hay ID, Goellner JR, Salomao D, Ebersold JR, Bergstralh EJ, Grant CS 1992 Follicular thyroid
carcinoma with capsular invasion alone: a non- threatening malignancy. Surgery 112:1130–1136. 496. Goldstein NS, Czako P, Neill JS 2000 Metastatic mini- mally invasive (encapsulated) follicular and Hu ¨rthle cell thyroid carcinoma: a study of 34 patients. Mod Pathol 13:123–130. 497. Sugino K, Ito K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, Yano Y, Uruno T, Akaishi J, Kameyama K, Ito K 2011 Prognosis and prognostic factors for distant metastases and tumor mortality in follicular thyroid carcinoma. Thyroid 21:751–757. 498. Sugino K, Kameyama K, Ito K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, Yano Y, Uruno T, Akaishi J, Suzuki A, Masaki C, Ito K 2012 Outcomes and prog- nostic factors of 251 patients with minimally invasive follicular thyroid carcinoma. Thyroid 22:798–804. 499. Ghossein RA, Hiltzik DH, Carlson DL, Patel S, Shaha A, Shah JP, Tuttle RM, Singh B 2006 Prognostic factors of recurrence in encapsulated Hu ¨rthle cell
carcinoma of the thyroid gland: a clinicopathologic study of 50 cases. Cancer 106:1669–1676. 500. Huang CC, Hsueh C, Liu FH, Chao TC, Lin JD 2011 Diagnostic and therapeutic strategies for minimally and widely invasive follicular thyroid carcinomas. Surg On- col20:1–6. 501. Lo CY, Chan WF, Lam KY, Wan KY 2005 Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival. Ann Surg 242:708–715. 502. Slade I, Bacchelli C, Davies H, Murray A, Abbaszadeh F, Hanks S, Barfoot R, Burke A, Chisholm J, Hewitt M, Jenkinson H, King D, Morland B, Pizer B, Prescott K,Saggar A, Side L, Traunecker H, Vaidya S, Ward P, Futreal PA, Vujanic G, Nicholson AG, Sebire N, Turn- bull C, Priest JR, Pritchard-Jones K, Houlston R, Stiller C, Stratton MR, Douglas J, Rahman N 2011 DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour pre- disposition syndrome. J
Med Genet 48:273–278. 503. Cetta F, Montalto G, Gori M, Curia MC, Cama A, Olschwang S 2000 Germline mutations of the APC gene in patients with familial adenomatous polyposis- associated thyroid carcinoma: results from a European cooperative study. J Clin Endocrinol Metab 85:286–292. 504. Harach HR, Williams GT, Williams ED 1994 Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm. Histopathology 25:549–561. 505. Hirokawa M, Maekawa M, Kuma S, Miyauchi A 2010 Cribriform-morular variant of papillary thyroid carcino-110 HAUGEN ET AL.
ma—cytological and immunocytochemical ﬁndings of 18 cases. Diagn Cytopathol 38:890–896. 506. Jung CK, Choi YJ, Lee KY, Bae JS, Kim HJ, Yoon SK, Son YI, Chung JH, Oh YL 2009 The cytological, clinical, and pathological features of the cribriform-morular variant of papillary thyroid carcinoma and mutation analysis of CTNNB1 and BRAF genes. Thyroid 19:905–913. 507. Koo JS, Jung W, Hong SW 2011 Cytologic character- istics and beta-catenin immunocytochemistry on smear slide of cribriform-morular variant of papillary thyroid carcinoma. Acta Cytol 55:13–18. 508. Ito Y, Miyauchi A, Ishikawa H, Hirokawa M, Kudo T, Tomoda C, Miya A 2011 Our experience of treat-ment of cribriform morular variant of papillary thyroid carcinoma; difference in clinicopathological features of FAP-associated and sporadic patients. Endocr J 58: 685–689. 509. Hollander MC, Blumenthal GM, Dennis PA 2011 PTEN loss in the continuum of common cancers, rare syn- dromes and mouse models. Nat Rev Cancer 11:289–301. 510. Laury
AR, Bongiovanni M, Tille JC, Kozakewich H, Nose V 2011 Thyroid pathology in PTEN-hamartoma tumor syndrome: characteristic ﬁndings of a distinct entity. Thyroid 21:135–144. 511. Nose V 2011 Familial thyroid cancer: a review. Mod Pathol 24(Suppl 2): S19–S33. 512. Harach HR, Soubeyran I, Brown A, Bonneau D, Longy M 1999 Thyroid pathologic ﬁndings in patients with Cowden disease. Ann Diagn Pathol 3:331–340. 513. Hemmings CT 2003 Thyroid pathology in four patients with Cowden’s disease. Pathology 35:311–314. 514. Volante M, Landolﬁ S, Chiusa L, Palestini N, Motta M, Codegone A, Torchio B, Papotti MG 2004 Poorly dif- ferentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer 100:950–957. 515. Sakamoto A, Kasai N, Sugano H 1983 Poorly differen- tiated carcinoma of the thyroid. A clinicopathologic en- tity for a high-risk group of papillary and follicular carcinomas. Cancer 52:1849–1855. 516. Carcangiu ML, Zampi G,
Rosai J 1984 Poorly differ- entiated (‘‘insular’’) thyroid carcinoma. A reinterpreta- tion of Langhans’ ‘‘wuchernde Struma’’. Am J Surg Pathol 8:655–668. 517. Pulcrano M, Boukheris H, Talbot M, Caillou B, Dupuy C, Virion A, De Vathaire F, Schlumberger M 2007Poorly differentiated follicular thyroid carcinoma: prog- nostic factors and relevance of histological classiﬁcation. Thyroid 17:639–646. 518. Papotti M, Botto MF, Favero A, Palestini N, Bussolati G 1993 Poorly differentiated thyroid carcinomas with pri- mordial cell component. A group of aggressive lesions sharing insular, trabecular, and solid patterns. Am J Surg Pathol 17:291–301. 519. Decaussin M, Bernard MH, Adeleine P, Treilleux I, Peix JL, Pugeat M, Tourniaire J, Berger N 2002 Thyroid carcinomas with distant metastases: a review of 111 cases with emphasis on the prognostic signiﬁcance of an insular component. Am J Surg Pathol 26:1007–1015. 520. Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A, Shah JP, Singh
B, Ghossein RA 2006 Poorly differentiated thyroid carcinomas deﬁned on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer 106:1286–1295.521. Gnemmi V, Renaud F, Do Cao C, Salleron J, Lion G, Wemeau JL, Copin MC, Carnaille B, Leteurtre E, Pattou F, Aubert S 2014 Poorly differentiated thyroid carcino- mas: application of the Turin proposal provides prog- nostic results similar to those from the assessment of high-grade features. Histopathology 64:263–273. 522. Sherman SI 1999 Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma. Semin Surg Oncol 16:12–15. 523. Yang L, Shen W, Sakamoto N 2013 Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. J Clin Oncol 31: 468–474. 524. Onitilo AA, Engel JM, Lundgren CI, Hall P, Thalib L, Doi SA 2009 Simplifying the TNM system for clinical use in differentiated thyroid cancer.
J Clin Oncol 27:1872–1878. 525. Mankarios D, Baade P, Youl P, Mortimer RH, Onitilo AA, Russell A, Doi SA 2013 Validation of the QTNM staging system for cancer-speciﬁc survival in patients with differentiated thyroid cancer. Endocrine 46:300–308. 526. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon HR III 1998 Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. Na- tional Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83:1012–1021. 527. Lang BH, Chow SM, Lo CY, Law SC, Lam KY 2007 Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers. Ann Surg 246:114–121. 528. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY 2007 Staging systems for papillary thyroid carcinoma: a re- view and comparison. Ann Surg 245:366–378. 529. Voutilainen PE,
Siironen P, Franssila KO, Sivula A, Haapiainen RK, Haglund CH 2003 AMES, MACIS and TNM prognostic classiﬁcations in papillary thyroid car- cinoma. Anticancer Res 23:4283–4288. 530. Yildirim E 2005 A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classiﬁcation systems. J Am Coll Surg 200:378–392. 531. Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS,Skarulis MC, Steward DL, Maxon HR, Sherman SI 2012 The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab 97:E878–E887. 532. Bischoff LA, Curry J, Ahmed I, Pribitkin E, Miller JL 2013 Is above age 45 appropriate for upstaging well- differentiated papillary thyroid cancer? Endocr Pract 19: 995–997. 533. Ganly I, Nixon IJ, Wang LY, Palmer FL, Migliacci JC, Aniss A, Sywak M, Eskander A,
Freeman JL, Campbell MJ, Shen WT, Vaisman F, Momesso D, Corbo R, Vaisman M, Shaha AM, Tuttle RM, Shah JP, Patel SG 2015 Survival from differentiated thyroid cancer: what has age got to do with it? Thyroid 25:1106–1114. 534. D’Avanzo A, Ituarte P, Treseler P, Kebebew E, Wu J, Wong M, Duh QY, Siperstein AE, Clark OH 2004 Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome. Thyroid 14:453–458.ATA THYROID NODULE/DTC GUIDELINES 111
535. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY 2007 Staging systems for follicular thyroid carcinoma: appli- cation to 171 consecutive patients treated in a tertiary referral centre. Endocr Relat Cancer 14:29–42. 536. Orlov S, Orlov D, Shaytzag M, Dowar M, Tabatabaie V, Dwek P, Yip J, Hu C, Freeman JL, Walﬁsh PG 2009 Inﬂuence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma. Head Neck 31:782–788. 537. Baek SK, Jung KY, Kang SM, Kwon SY, Woo JS, Cho SH, Chung EJ 2010 Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid 20:147–152. 538. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A 2010 Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify
the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341–1349. 539. Vaisman F, Momesso D, Bulzico DA, Pessoa CH, Dias F, Corbo R, Vaisman M, Tuttle RM 2012 Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol (Oxf) 77:132–138. 540. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W 2006 European consensus for the manage- ment of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803. 541. Camargo R, Corigliano S, Friguglietti C, Gauna A, Harach R, Munizaga F, Niepomniszcze H, Pitoia F, Pretell E, Vaisman M, Ward LS, Wohllk N, Tomimori E 2009 Latin American Thyroid Society recommendations for the management of thyroid nodules. Arq Bras En- docrinol Metabol 53:1167–1175. 542. Castagna MG, Maino F, Cipri C, Belardini V, Theo- doropoulou A, Cevenini G, Pacini F 2011 Delayed risk stratiﬁcation, to